Compounds and compositions as protein kinase inhibitors

Details Compounds and compositions as protein kinase inhibitors Compounds and compositions as protein kinase inhibitors

2007-11-20

2011-10-18

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S323000

Reexamination Certificate

active

08039479

ABSTRACT:
The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

REFERENCES:
patent: 3361749 (1968-01-01), Matter et al.
patent: 3432493 (1969-03-01), Short
patent: 5138058 (1992-08-01), Geisen et al.
patent: 5958935 (1999-09-01), Davis et al.
patent: 6048866 (2000-04-01), Hutchings et al.
patent: 6093716 (2000-07-01), Davis et al.
patent: 6114333 (2000-09-01), Davis et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 6593326 (2003-07-01), Bradbury et al.
patent: 7241769 (2007-07-01), Stadtmueller et al.
patent: 7514446 (2009-04-01), Davis-Ward et al.
patent: 7671063 (2010-03-01), Baenteli et al.
patent: 2006/0100227 (2006-05-01), Baenteli et al.
patent: 2006/0247241 (2006-11-01), Garcia-Echeverria et al.
patent: 2008/0132504 (2008-06-01), Garcia-Echeverria et al.
patent: 2008/0293708 (2008-11-01), Kawahara et al.
patent: 2009/0131436 (2009-05-01), Imbach et al.
patent: 1054004 (2000-11-01), None
patent: 1184376 (2005-02-01), None
patent: WO 97/19065 (1997-05-01), None
patent: 9841512 (1998-09-01), None
patent: WO 99/50250 (1999-10-01), None
patent: WO 00/12485 (2000-03-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 00/78731 (2000-12-01), None
patent: 0125220 (2001-04-01), None
patent: WO 01/60816 (2001-08-01), None
patent: 0164654 (2001-09-01), None
patent: 0164656 (2001-09-01), None
patent: WO 01/64655 (2001-09-01), None
patent: WO 01/85699 (2001-11-01), None
patent: WO 01/85700 (2001-11-01), None
patent: 0256888 (2002-07-01), None
patent: WO 03/016306 (2003-02-01), None
patent: WO 03/018021 (2003-03-01), None
patent: WO 03/030909 (2003-04-01), None
patent: WO 03/063794 (2003-08-01), None
patent: WO 03/066601 (2003-08-01), None
patent: WO 03/078404 (2003-09-01), None
patent: WO 03/094920 (2003-11-01), None
patent: WO 03/095448 (2003-11-01), None
patent: WO 2004/002964 (2004-01-01), None
patent: WO 2004/046118 (2004-06-01), None
patent: 2004056786 (2004-07-01), None
patent: WO 2004/074244 (2004-09-01), None
patent: WO 2004/080980 (2004-09-01), None
patent: WO 2005/013996 (2005-02-01), None
patent: WO 2005/016894 (2005-02-01), None
patent: WO 2005/026130 (2005-03-01), None
patent: WO 2005/026158 (2005-03-01), None
patent: WO 2006/021454 (2006-03-01), None
patent: WO 2006/021457 (2006-03-01), None
patent: 2006068770 (2006-06-01), None
patent: 2006/074057 (2006-07-01), None
patent: WO 2006/133426 (2006-12-01), None
patent: WO 2008/051547 (2008-05-01), None
patent: 2009032694 (2009-03-01), None
patent: 2009032703 (2009-03-01), None
Galkin, et al., “Identification of NVP-TAE684, a potent, selective, and efficacious inhibitors of NPM-ALK”, PNAS, vol. 104, No. 1, pp. 270-275, Jan. 2, 2007.
Traxler, Peter M. , “Protein Tyrosine Kinase Inhibitors in Cancer Treatment,” Expert Opinion on Therapeutic Patents, vol. 7, No. 6, pp. 571-588, 1997.
Simone et al., Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1997.
Basford et al., CAPLUS Abstract 41:763, pp. 7810-7812,1947.
Coopman et al., “The Syk Tyrosine Kinase Suppresses Malignant Growth of Human Breast Cancer Cells,” Nature, vol. 406, pp. 742-747, Aug. 17, 2000.
USPTO Notice of Allowance, dated Oct. 4, 2010, of U.S. Appl. No. 10/568,367 (U.S. Patent Publication No. 2008/0132504).
USPTO Notice of Allowance, dated Feb. 7, 2011, of U.S. Appl. No. 10/549,250 (U.S. Patent Publication No. 2006/0247241).
USPTO Notice of Allowance, dated Dec. 27, 2010, of U.S. Appl. No. 10/507,060 (U.S. Patent Publication No. 2006/0100227).
USPTO Notice of Allowance, dated Nov. 12, 2010, of U.S. Appl. No. 11/660,714 (U.S. Patent Publication No. 2008/0293708).
Ghosh et al., “2,4-Bis(arylamino)-5-methylpyrimidines as Antimicrobial Agents,” Journal of Medicinal Chemistry, vol. 10, No. 5, pp. 974-975, Sep. 1967.
Ghosh Dolly, “2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents,” Journal of the Indian Chemical Society, vol. 58, No. 5, pp. 512-513, May 1981.
Ghoneim et al., “Synthesis and Evaluation of some 2-, 4- and 2,4-Di-substituted-6-methylpyrimidine Derivatives for Antimicrobial Activity,” Journal of the Indian Chemical Society, vol. 63, No. 10, pp. 914-917, Oct. 1986.
Van Seventer et al., “Focal adhesion kinase regulates β1 integrin-dependent T cell migration through an HEF1 effector pathway,” European Journal of Immunology, 31: 1417-1427, 2001.
Dirks et al., “Expression and Functional Analysis of the Anaplastic Lymphoma Kinase (ALK) Gene in Tumor Cell Lines,” Int. J. Cancer: 100, 49-56, 2002.
Osajima-Hakomori et al., “Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma,” American Journal of Pathology, vol. 167, No. 1, pp. 213-222, Jul. 2005.

Affiliated with

Also associated with

Rating

Compounds and compositions as protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and compositions as protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and compositions as protein kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4285574